A High-Throughput Screening Assay for Fungicidal Compounds against Cryptococcus neoformans

This publication has 31 references indexed in Scilit:

• Epidemiology of Cryptococcal Meningitis in the US: 1997–2009
  PLOS ONE, 2013
• Role of CTR4 in the Virulence of Cryptococcus neoformans
  mBio, 2012
• Selective inhibition of CD4 ⁺ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors
  Proceedings of the National Academy of Sciences, 2012
• Cryptococcus neoformans Requires a Functional Glycolytic Pathway for Disease but Not Persistence in the Host
  mBio, 2011
• How Sweet it is! Cell Wall Biogenesis and Polysaccharide Capsule Formation in Cryptococcus neoformans
  Annual Review of Microbiology, 2009
• Comparison of 24-Hour and 48-Hour Voriconazole MICs as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) in Three Laboratories: Results Obtained with 2,162 Clinical Isolates of Candida spp. and Other Yeasts
  Journal of Clinical Microbiology, 2009
• Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV‐Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients
  Clinical Infectious Diseases, 2009
• Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS
  AIDS, 2009
• Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice
  Cancer Chemotherapy and Pharmacology, 2008
• Role of a CUF1/CTR4 copper regulatory axis in the virulence of Cryptococcus neoformans
  Journal of Clinical Investigation, 2007